On the regular-filing basis, annual revenue rose from KRW 82.6 billion in 2022 to KRW 97.9 billion in 2023 (up 18.5%), KRW 107 billion in 2024 (up 9.3%), and KRW 108 billion in 2025 (up 1.0%), growing for three consecutive years from 2023 through 2025, with 2025 the largest year of 2022 to 2025.
Over the same period operating profit fell from KRW 14.9 billion to KRW 12.8 billion (down 14.5%) and KRW 6.51 billion (down 49.0%), and in 2025 the company posted an operating loss of KRW 243 million after turning negative. The operating margin declined from 18.1% to 13.0%, then 6.1%, and -0.2% in 2025.
Net income attributable to controlling shareholders went from KRW 13.9 billion in 2022 to KRW 12.5 billion in 2023 (down 10.2%), then a loss of KRW 1.8 billion in 2024, before returning to a KRW 758 million profit in 2025. Total net income including non-controlling interests was KRW 628 million in 2025.
The debt ratio rose from 20.7% in 2022 to 56.7% in 2025, when total liabilities were KRW 47.5 billion and total equity KRW 83.8 billion. Operating cash flow fell from KRW 13.3 billion in 2024 to KRW 5.26 billion in 2025.
By quarter, the company moved from an operating loss of KRW 1.66 billion in the third quarter of 2025 on KRW 21.8 billion revenue to an operating profit of KRW 1.38 billion on KRW 34 billion revenue in the fourth quarter, which it attributed to large government tender wins in Russia, Turkey and Lebanon.
First-quarter 2026 revenue fell 25.4% quarter on quarter to KRW 25.4 billion, with an operating loss of KRW 1.58 billion. Analysts attribute that quarter's weakness to dental CT sales declines that outweighed C-arm growth.
Operating profit returned to KRW 249 million in the second quarter and KRW 2.7 billion in the third, but the third quarter still showed a KRW 1.74 billion net loss attributable to controlling shareholders. Net income attributable to controlling shareholders over the latest four quarters totaled KRW 1.86 billion.